HPN

Serine protease hepsin · P05981 · HPN on Sugi Atlas →

16,716 patent compounds predicted against HPN, 10,720 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1244355	0.54	7/20
SCHEMBL1839478	0.53	7/20
SCHEMBL1839480	0.53	7/20
Methyl P-Toluenesulfonyl-L-Argininate (SCHEMBL324561)	0.52	7/20
Methyl P-Toluenesulfonyl-L-Argininate (SCHEMBL1034821)	0.51	7/20
Hydrochloric Acid (SCHEMBL1439227)	0.46	7/20
SCHEMBL1509766	0.53	5/20
SCHEMBL1509767	0.53	5/20
SCHEMBL284484	0.47	5/20
4-Methylbenzimidamide (SCHEMBL1050355)	0.47	5/20
SCHEMBL1115907	0.47	5/20
SCHEMBL284482	0.44	5/20
SCHEMBL1421131	0.44	5/20
SCHEMBL1438434	0.40	5/20
SCHEMBL1325070	0.70	4/20
SCHEMBL1325228	0.56	4/20
SCHEMBL1176564	0.48	4/20
SCHEMBL1176567	0.48	4/20
SCHEMBL200245	0.47	4/20
SCHEMBL200247	0.47	4/20

Clinical trials — most relevant to HPN by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effect of Evolocumab on Vascular Function	PHASE4	COMPLETED
Clinical Trial With Aprotinin in the Acute Respiratory Distress Syndrome Treatment	PHASE3	NOT_YET_RECRUITING
Vitamin E, Selenium, and Soy Protein in Preventing Cancer in Patients With High-Grade Prostate Neoplasia	PHASE3	COMPLETED
Strategies to Reduce Organic Muscle Atrophy in the Intensive Care Unit	PHASE2/PHASE3	WITHDRAWN
Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults	PHASE3	COMPLETED
Photodynamic Therapy Using HPPH in Treating Patients With Obstructive Esophageal Tumors	PHASE1/PHASE2	COMPLETED
A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Comparative Clinical Study to Evaluate the Possible Efficacy and Safety of Oral N-Acetyl Cysteine Versus Rectal Diclofenac in the Prevention of Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis	PHASE1/PHASE2	COMPLETED
A Pilot Study of Use of Calcium Channel Blocker to Decrease Inflammation and Pain in Hereditary Pancreatitis	PHASE1/PHASE2	COMPLETED
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus	PHASE2	COMPLETED
Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions	PHASE1	COMPLETED
A Study of HMPL-689 in Patients With Lymphomas Failed of Standard of Care or no Standard of Care Existed	PHASE1	COMPLETED
HPPH Photodynamic Therapy for Patients With Esophageal Cancer	PHASE1	UNKNOWN
Photodynamic Therapy With HPPH in Treating Patients With Non-Small Cell Lung Cancer	PHASE1	COMPLETED
The Safety, Tolerability, and Initial Efficacy of HX009 in Patients With Advanced Malignancies	PHASE1	COMPLETED
Study of LVGN7409 (CD40 Agonist Antibody) in Locally Advanced, Metastatic or Recurrent/Refractory Malignancy	PHASE1	COMPLETED
Acute Pancreatitis Targets (APT) Study	nan	COMPLETED
Genetic Determinism of Epithelial Barrier Defects in Irritable Bowel Syndrome	nan	WITHDRAWN
Influence of Statins in Artery Aneurysms	nan	UNKNOWN
Genetic Mechanisms of Chronic Obstructive Pulmonary Disease (COPD)	nan	COMPLETED
Unraveling Genetics of HypoPhosPhatasia (HPP Genetics)	nan	COMPLETED
Genes-in-Action - Hepcidin Regulation of Iron Supplementation	nan	COMPLETED
Disorders of the Acute Phase Response Following Trauma and Invasive Surgery	nan	ENROLLING_BY_INVITATION
Hereditary Tubulointerstitial Nephritis	nan	COMPLETED
Integrated Proteomic HPLC-ESI-MS Analysis of Salivary Peptides of Preterm Newborns: a Pilot Study	nan	COMPLETED
Genetic Linkage Study for Hereditary Pancreatitis	nan	COMPLETED
Aminophylline to Prevent Acute Kidney Injury in Children After Cardiac Surgery	nan	COMPLETED
Urine and Serum Concentrations of Pregnancy-Associated Compounds During Gestation	nan	COMPLETED
Evaluation of OMEGAVEN 10%® (n-3 EFA Lipid Emulsion) in Home Parenteral Nutrition-associated Liver Disease	nan	COMPLETED
Prevalence Assessment and Characterization of Psychological Disorders Associated With Hypobetalipoproteinemia	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a HPN binder may also engage these)

Protein	Name	Similarity
Q5R5E8	—	1.000	Q5R5E8 →
Q05511	—	0.998	Q05511 →
O35453	—	0.993	O35453 →
F7	Coagulation factor VII	0.989	landscape →
Q2F9P2	—	0.987	Q2F9P2 →
D3ZTE0	—	0.987	D3ZTE0 →
P69526	—	0.986	P69526 →
Q3UZ09	—	0.985	Q3UZ09 →
TMPRSS4	Transmembrane protease serine 4	0.985	landscape →
P22457	—	0.984	P22457 →
P57727	—	0.984	P57727 →
Q6IE64	—	0.984	Q6IE64 →
P69525	—	0.984	P69525 →
P00745	—	0.984	P00745 →
TMPRSS6	Transmembrane protease serine 6	0.983	landscape →
P00743	—	0.983	P00743 →
Q9ER04	—	0.983	Q9ER04 →
Q80YC5	—	0.983	Q80YC5 →
Q9GLP2	—	0.983	Q9GLP2 →
Q8VCA5	—	0.983	Q8VCA5 →
O97507	—	0.982	O97507 →
P22891	—	0.982	P22891 →
Q28661	—	0.982	Q28661 →
P98139	—	0.982	P98139 →
Q9R098	—	0.981	Q9R098 →
PROC	Vitamin K-dependent protein C	0.981	landscape →
Q7Z410	—	0.981	Q7Z410 →
ST14	Suppressor of tumorigenicity 14 protein	0.981	landscape →
Q8K1T0	—	0.981	Q8K1T0 →
P31394	—	0.981	P31394 →